Overview

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Phase:
N/A
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Alemtuzumab
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Melphalan
Mesna
Vidarabine